Pre-emptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients

Transplantation

Volumn 81, Issue 2, 2006, Pages 139-145

  Strippoli, Giovanni F M ^a,b,e   Hodson, Elisabeth M ^a,c   Jones, Cheryl ^d,e   Craig, Jonathan C ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antiviral prophylaxis; Cytomegalovirus infection; Preemptive treatment

Indexed keywords

ACICLOVIR; FOSCARNET; GANCICLOVIR; PLACEBO; VALACICLOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ACUTE GRAFT REJECTION; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EMBASE; HUMAN; MEDLINE; MORTALITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZATION; RECIPIENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; VIREMIA; CONTROLLED CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; OPPORTUNISTIC INFECTION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TRANSPLANTATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTS; VIREMIA;

EID: 33644857729     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000183970.71366.da     Document Type: Article

References (17)

1. Hart GD, Paya CV. Prophylaxis for CMV should now replace preemptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73-81.
2. The EBPG Group on Renal Transplantation. The transplant recipient from initial hospitalization to 1 year post-transplant. Nephrol Dial Transplant 2000; 15: 52-85.
3. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, Vimalachandra D, Craig JC. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365(9477): 2105-15.
4. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-86.
5. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Trasnplantation 1992; 53: 68-72.
6. Dickersin K, Scherer R, Letebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309: 1286-1291.
7. Schultz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986; 7: 177-188.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
10. Sing N, Yu VL, Mieles L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. Ann Intern Med 1994; 120: 375-381.
11. Sing N, Paterson DL, Gayowsky T, et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus i.v. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients. Transplantation 2000; 70: 717-722.
12. Jung C, Engelmann E, Borner K, Offermann G. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney trasnplantation. Transplant Proc 2001; 33: 3621-2623.
13. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118-125.
14. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649.
15. Paya CV, Wilson JA, Espy MJ, et al. Preemptive us of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infectious Dis 2002; 185: 854-860.
16. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-1311.
17. Sagedal S, Nordal KP, Hartmann A, et al. Pre-emptive therapy of CM-Vpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study. Nephrol Dial Transplant 2003; 18: 1899-1908.